{"product_id":"innovatecorp-bcg-matrix","title":"Innovate Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the Innovate BCG Matrix to see which offerings are driving growth, which fund the portfolio, and which need reassessment—this preview highlights key signals across Stars, Cash Cows, Dogs, and Question Marks. Purchase the full BCG Matrix for a complete quadrant-by-quadrant breakdown, data-backed recommendations, and downloadable Word and Excel files to guide strategic decisions and capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR2 Technologies Aesthetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR2 Technologies Aesthetics is a Star in Innovate BCG Matrix, posting an 88.2% revenue rise in Q2 2025 and driving holding growth.\u003c\/p\u003e\n\u003cp\u003eGlacial fx system sales jumped 124%+ as R2 entered Belgium and the Netherlands, fueling international unit expansion.\u003c\/p\u003e\n\u003cp\u003eIt needs heavy capital for global scaling—capex and marketing—yet its dominant aesthetic dermatology niche makes it the holding’s primary growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMediBeacon TGFR System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Transdermal GFR System (TGFR) won FDA approval in Jan 2025 and NMPA approval in 2025, opening access to a roughly $7.0B global kidney-function diagnostics market; early commercial forecasts target $150–300M revenue by 2027 assuming 2–4% market share. \u003c\/p\u003e\n\u003cp\u003eTGFR’s proprietary sensor creates a durable moat vs invasive iohexol tests; gross margins are modeled at 65% with initial CAPEX ~ $40–60M for sales and distribution buildout through Q4 2025 to scale adoption. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDBM Global Data Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDBM Global Data Centers sits as a Star in Innovate BCG: its specialized structural-steel fabrication for hyperscale data centers grew revenue 42% year-over-year in 2025, capturing roughly 28% share of the high-complexity steel market for data centers in North America and Europe.\u003c\/p\u003e\n\u003cp\u003eThe AI and cloud surge drove a project pipeline exceeding $1.6 billion backlog at end-2025; gross margins improved to 18% as scale rose, but working capital tied up 24% of revenue to fund multi-year builds and prefabrication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Gene Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovate Corp’s Pansend Life Sciences leads in gene therapies, targeting a market growing at ~18% CAGR to 2028 and capturing a meaningful personalized-medicine niche versus bigger rivals.\u003c\/p\u003e\n\u003cp\u003eMaintaining this star requires sustained R\u0026amp;D: Pansend spends ~22% of revenue on R\u0026amp;D (2024), needs continued investment to retain technological edge and meet complex next-gen biologics regulations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket CAGR ~18% to 2028\u003c\/li\u003e\n\u003cli\u003ePansend R\u0026amp;D ≈22% of revenue (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: personalized medicine, niche market share\u003c\/li\u003e\n\u003cli\u003eRisk: high capex, regulatory complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfrastructure Backlog Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company’s ability to convert its record 1.6 billion dollar adjusted backlog into active revenue streams is a Star-level operational priority, since turning that backlog into revenue drives near-term growth and long-term margin expansion.\u003c\/p\u003e\n\u003cp\u003eAs of Q3 2025, the Infrastructure segment posted a 45.4% revenue surge, led by kickoff of massive commercial and industrial projects; disciplined project management and working capital are required to secure margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.6B adjusted backlog\u003c\/li\u003e\n\u003cli\u003eQ3 2025 revenue +45.4%\u003c\/li\u003e\n\u003cli\u003eFocus: project controls, cash flow, capex\u003c\/li\u003e\n\u003cli\u003eGoal: convert to stable high-margin cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovate’s 2025 Surge: R2, DBM, Pansend Power Double‑Digit Growth and Big Backlog\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: R2 Technologies Aesthetics, DBM Global Data Centers, Pansend Life Sciences—high-growth, high-share units driving Innovate’s 2025 revenue surge; key metrics: R2 Q2 2025 rev +88.2%, Glacial fx sales +124%+, TGFR FDA Jan 2025, TGFR 2027 rev target $150–300M; DBM 2025 rev +42%, $1.6B backlog; Pansend R\u0026amp;D ≈22%, market CAGR ~18% to 2028.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2025 metric\u003c\/th\u003e\n\u003cth\u003eKey needs\/risks\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR2\u003c\/td\u003e\n\u003ctd\u003eQ2 rev +88.2%\u003c\/td\u003e\n\u003ctd\u003eCapex, marketing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDBM\u003c\/td\u003e\n\u003ctd\u003eRev +42%, $1.6B backlog\u003c\/td\u003e\n\u003ctd\u003eWorking capital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePansend\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D 22%, CAGR 18%\u003c\/td\u003e\n\u003ctd\u003eRegulatory R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review with quadrant-specific strategies, investment guidance, competitive threats, and trend-driven recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Innovate BCG Matrix placing each business unit in a quadrant for quick strategic clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDBM Global Structural Steel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDBM Global Structural Steel, Innovate Corp’s largest revenue driver, reported $1.12B revenue and $220M EBITDA in FY2025, reflecting mature market leadership in U.S. commercial structural steel.\u003c\/p\u003e\n\u003cp\u003eDespite project timing swings, DBM delivers steady cash flow—free cash flow of $150M in 2025—funding Innovate’s high-growth Life Sciences units and servicing $400M corporate debt.\u003c\/p\u003e\n\u003cp\u003eIts reputation and scale sustain ~19.6% EBITDA margin with low incremental capex (capex\/sales ~2.5%), keeping returns high with minimal new infrastructure spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHC2 Broadcasting Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Spectrum segment, via HC2 Broadcasting, operates one of the largest over-the-air station groups in the US, serving over 100 markets and reaching ~25 million viewers as of 2025; it generates steady distribution fees and local\/national advertising revenue, producing predictable cash flow. \u003c\/p\u003e\n\u003cp\u003eWith 2024 estimated EBITDA margins near 40% for the unit and low ongoing capex (licenses and transmitters), HC2 functions as a classic cash cow despite low market growth, funding corporate liquidity and M\u0026amp;A. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial Construction Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Industrial Construction Services unit, within Infrastructure, runs long-term maintenance and fabrication contracts for energy and transport—sectors with 3–5% annual demand growth and 80–90% repeat-contract rates—yielding ~12% operating margins in 2025 and 6–7% free-cash-flow conversion, which Innovate Corp uses to offset volatility in speculative holdings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpectrum License Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovate Corp holds 2.7 billion MHz-POPs of licensed spectrum, a durable intangible asset in a stable regulatory regime that trades like a land bank and required only low maintenance costs.\u003c\/p\u003e\n\u003cp\u003eThese licenses generated estimated lease and reserve value of about $1.1 billion as of 2025 year-end, anchoring cash flow and underwriting experimental datacasting pilots with limited capex.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: 2.7B MHz-POPs × implied market lease value ≈ $1.1B; this stabilizes free cash flow while tech adoption evolves.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.7 billion MHz-POPs spectrum\u003c\/li\u003e\n\u003cli\u003eLow ongoing costs; high optionality\u003c\/li\u003e\n\u003cli\u003eEstimated $1.1B lease\/reserve value (2025)\u003c\/li\u003e\n\u003cli\u003eBacks experimental datacasting pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Life Sciences Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Life Sciences Royalties: select mature Pansend assets now produce steady royalties after commercialization, requiring zero further R\u0026amp;D and yielding about $28m annual cash flow in 2025, covering ~45% of Innovate BCG Matrix holding overhead.\u003c\/p\u003e\n\u003cp\u003eThese royalties sustain operations and seed Question Mark projects; recent payout stability shows 6% CAGR since 2021 and gross margins near 85%, so cash is low-risk funding for next-gen development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 royalties: $28m\u003c\/li\u003e\n\u003cli\u003eCAGR 2021–25: 6%\u003c\/li\u003e\n\u003cli\u003eGross margin: ~85%\u003c\/li\u003e\n\u003cli\u003eCovers ~45% of overhead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash Cows 2025: DBM Steel $150M FCF, HC2 $1.1B spectrum, steady construction \u0026amp; royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows (2025): DBM Steel—$1.12B rev, $220M EBITDA, $150M FCF; HC2 Broadcasting—~40% EBITDA, reaches ~25M viewers, spectrum lease value $1.1B; Industrial Construction—~12% op margin, 6–7% FCF conversion; Life Sciences royalties—$28M cash, 6% CAGR since 2021.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2025 Rev\/Value\u003c\/th\u003e\n\u003cth\u003eEBITDA\/ Margin\u003c\/th\u003e\n\u003cth\u003eFCF\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDBM Steel\u003c\/td\u003e\n\u003ctd\u003e$1.12B\u003c\/td\u003e\n\u003ctd\u003e$220M \/ 19.6%\u003c\/td\u003e\n\u003ctd\u003e$150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHC2 Broadcasting\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003ctd\u003eLease value $1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustrial Construction\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003ctd\u003eFCF conv 6–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife Sciences Royalties\u003c\/td\u003e\n\u003ctd\u003e$28M\u003c\/td\u003e\n\u003ctd\u003e~85% gross\u003c\/td\u003e\n\u003ctd\u003e$28M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eInnovate BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Innovate BCG Matrix report you'll receive after purchase—no watermarks, no placeholder content—just a fully formatted, strategy-ready document crafted for clarity and decision-making. This preview mirrors the final downloadable file, designed by strategy experts with market-backed insights and ready to edit, print, or present. Upon purchase you’ll instantly unlock the complete report for immediate use—no surprises, no revisions required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747955913081,"sku":"innovatecorp-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/innovatecorp-bcg-matrix.png?v=1772203260","url":"https:\/\/growthsharematrix.com\/products\/innovatecorp-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}